In AML, the identification of specific mutations, such as FLT3-ITD, TP53, and NPM1, plays a crucial role in stratifying patients’ risk profiles, directly influencing prognosis and treatment strategies [59,60]. This evidence concerns the gene TP53 and acute myeloid leukemia.